JPWO2019203255A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019203255A5 JPWO2019203255A5 JP2020514407A JP2020514407A JPWO2019203255A5 JP WO2019203255 A5 JPWO2019203255 A5 JP WO2019203255A5 JP 2020514407 A JP2020514407 A JP 2020514407A JP 2020514407 A JP2020514407 A JP 2020514407A JP WO2019203255 A5 JPWO2019203255 A5 JP WO2019203255A5
- Authority
- JP
- Japan
- Prior art keywords
- cancer
- cells
- administration
- emt
- anticancer drug
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010028980 Neoplasm Diseases 0.000 claims 19
- 201000011510 cancer Diseases 0.000 claims 19
- 239000002246 antineoplastic agent Substances 0.000 claims 6
- 229940041181 antineoplastic drug Drugs 0.000 claims 6
- 210000004027 cell Anatomy 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 210000002220 organoid Anatomy 0.000 claims 5
- 229940079593 drug Drugs 0.000 claims 4
- 239000003814 drug Substances 0.000 claims 4
- 210000001519 tissue Anatomy 0.000 claims 4
- 238000012258 culturing Methods 0.000 claims 2
- 238000012216 screening Methods 0.000 claims 2
- 210000002536 stromal cell Anatomy 0.000 claims 2
- 210000003556 vascular endothelial cell Anatomy 0.000 claims 2
- 230000002265 prevention Effects 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
Claims (3)
- 癌微小環境を再構成する組織中の癌細胞及び／又は間質細胞において、抗癌剤の投与前と投与後のEMT関連分子の発現レベルを測定し、抗癌剤の投与前よりも投与後の発現レベルが上昇しているEMT関連分子を癌の治療抵抗性に関与していると判定する、癌の治療抵抗性に関与する分子のスクリーニング方法であって、癌微小環境を再構成する組織が、癌細胞を間葉系細胞及び血管内皮細胞と共培養することにより作製された癌オルガノイド及び／又は該癌オルガノイドから作製されたゼノグラフトである前記方法。
- 癌微小環境を再構成する組織中の癌細胞及び／又は間質細胞において、抗癌剤の投与前と投与後のEMT関連分子の発現レベルを測定し、抗癌剤の投与前よりも投与後の発現レベルが上昇しているEMT関連分子を癌の治療抵抗性に関与していると判定し、そのEMT関連分子の機能を阻害できる物質を癌の治療抵抗性に有効な薬剤であると判定する、癌の治療抵抗性に有効な薬剤のスクリーニング方法であって、癌微小環境を再構成する組織が、癌細胞を間葉系細胞及び血管内皮細胞と共培養することにより作製された癌オルガノイド及び／又は該癌オルガノイドから作製されたゼノグラフトである前記方法。
- 癌の治療抵抗性に有効な薬剤が癌の再発の治療及び／又は予防に有効な薬剤である請求項２記載の方法。
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2018080585 | 2018-04-19 | ||
| JP2018080585 | 2018-04-19 | ||
| PCT/JP2019/016421 WO2019203255A1 (ja) | 2018-04-19 | 2019-04-17 | 再構成癌組織を用いた薬剤評価方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPWO2019203255A1 JPWO2019203255A1 (ja) | 2021-06-10 |
| JPWO2019203255A5 true JPWO2019203255A5 (ja) | 2022-03-02 |
Family
ID=68238962
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020514407A Pending JPWO2019203255A1 (ja) | 2018-04-19 | 2019-04-17 | 再構成癌組織を用いた薬剤評価方法 |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JPWO2019203255A1 (ja) |
| WO (1) | WO2019203255A1 (ja) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPWO2021221179A1 (ja) * | 2020-04-28 | 2021-11-04 | ||
| WO2023238939A1 (ja) * | 2022-06-09 | 2023-12-14 | 慶應義塾 | 癌の再燃若しくは再発の予防剤又は治療剤及びそのスクリーニング方法 |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014151606A2 (en) * | 2013-03-15 | 2014-09-25 | Oncomed Pharmaceuticals, Inc. | Methods of treating pancreatic cancer |
| US20170023576A1 (en) * | 2014-04-04 | 2017-01-26 | Oncomed Pharmaceuticals, Inc. | Notch3 antibodies and uses thereof |
| WO2016089208A2 (en) * | 2014-12-04 | 2016-06-09 | Stichting Maastricht Radiation Oncology "Maastro-Clinic" | Sulfonamide, sulfamate and sulfamide derivatives of anti-cancer agents |
-
2019
- 2019-04-17 JP JP2020514407A patent/JPWO2019203255A1/ja active Pending
- 2019-04-17 WO PCT/JP2019/016421 patent/WO2019203255A1/ja active Application Filing
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Tocchetti et al. | From molecular mechanisms to clinical management of antineoplastic drug-induced cardiovascular toxicity: a translational overview | |
| Sun et al. | Therapeutic strategies targeting cancer stem cells and their microenvironment | |
| JP2019150584A5 (ja) | ||
| Cragg et al. | New horizons for old drugs and drug leads | |
| Li et al. | Turmeric extract, with absorbable curcumin, has potent anti-metastatic effect in vitro and in vivo | |
| Wei et al. | Large-scale and rapid preparation of nanofibrous meshes and their application for drug-loaded multilayer mucoadhesive patch fabrication for mouth ulcer treatment | |
| Jain et al. | Engineering a piperine eluting nanofibrous patch for cancer treatment | |
| JPWO2019203255A5 (ja) | ||
| Ribatti | The Chick Embryo Chorioallantoic Membrane in the Study of Angiogenesis and Metastasis: The CAM assay in the study of angiogenesis and metastasis | |
| Lin et al. | Sulforaphane potentiates the efficacy of imatinib against chronic leukemia cancer stem cells through enhanced abrogation of Wnt/β-catenin function | |
| EP3750540B1 (en) | Choroidal neovascularization suppressor or drusen formation suppressor | |
| JP2008522738A5 (ja) | ||
| Xu et al. | Synergistic effect and molecular mechanisms of traditional Chinese medicine on regulating tumor microenvironment and cancer cells | |
| Venkatachalam et al. | Antidiabetic activity of Lantana camara Linn fruits in normal and streptozotocin-induced diabetic rats | |
| Lertsuphotvanit et al. | Borneol-based antisolvent-induced in situ forming matrix for crevicular pocket delivery of vancomycin hydrochloride | |
| Dang et al. | Local doxorubicin delivery via 3D‐printed porous scaffolds reduces systemic cytotoxicity and breast cancer recurrence in mice | |
| Fouani et al. | Targeting oncogenic nuclear factor kappa B signaling with redox-active agents for cancer treatment | |
| Stewart et al. | Cytocidal activity and proliferative ability of macrophages infiltrating the EMT6 tumor | |
| Zhao et al. | Salvia miltiorrhiza in breast cancer treatment: A review of its phytochemistry, derivatives, nanoparticles, and potential mechanisms | |
| Leporini et al. | A comprehensive safety evaluation of trabectedin and drug–drug interactions of trabectedin-based combinations | |
| CN104870001B (zh) | 用作消炎或免疫抑制有效成分的飞燕草素络合物 | |
| Gunnellini et al. | Therapeutic activity of lenalidomide in mantle cell lymphoma and indolent non‐Hodgkin’s lymphomas | |
| Veysanoglu et al. | In vitro and in vivo evaluation of multi-target-directed Rivastigmine/Memantine/Gingko biloba-loaded nanofibers against Alzheimer's disease | |
| Abdel-Hafez et al. | Effect of nicotine on the structure of cochlea of guinea pigs | |
| Gangwar et al. | Utilizing guar gum for development of “tabs in cap’system of losartan potassium for chronotherapeutics |